Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Candesartan 8mg
Amlodipine 5mg
CKD-330 8/5mg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Healthy male volunteer, Candesartan, Amlodipine
Eligibility Criteria
Inclusion Criteria:
- Healthy male volunteer in the age of 19-45
- Body weight ≥ 55 kg and in the range of calculated IBW ±20%
- Subject without a hereditary problems, chronic disease and morbid symptom
- Suitable clinical laboratory test values
- Subject who sign on an informed consent form willingly
Exclusion Criteria:
- Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
- Gastrointestinal disease or gastrointestinal surgery
- History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
- Galactose intolerance
- Sitting systolic blood pressure ≥ 140 mmHg or< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 beats per minute
- Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range
- Serum Creatinine > upper limit of normal range
- Drug abuse
- Subject treated metabolizing enzyme inducers or inhibitors within 1 month
- Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
- Subject treated Investigational product(include Bioequivalence test) within 3 months
- Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
- Continuously taking Alcohol > 21 units/week
- Cigarette > 10 cigarettes/day
- Subjects with planning of dental treatment or any surgery
- Another clinical condition in judgement of investigator
Sites / Locations
- Chungnam National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Candesartan and Amlodipine
CKD-330
Arm Description
Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
CKD-330 8/5mg, PO, 1day or 22day
Outcomes
Primary Outcome Measures
Cmax(Maximum Plasma Concentration) of Candesartan
AUCt(Area Under the Plasma Concentration-time curve) of Candesartan
Cmax(Maximum Plasma Concentration) of Amlodipine
AUCt(Area Under the Plasma Concentration-time curve) of Amlodipine
Secondary Outcome Measures
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Candesartan
tmax(Time to reach the maximum concentration) of Candesartan
t1/2β(Time for C max to drop in half) of Candesartan
CL/F(Clearance/Bioavailability) of Candesartan
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Amlodipine
tmax(Time to reach the maximum concentration) of Amlodipine
t1/2β(Time for C max to drop in half) of Amlodipine
CL/F(Clearance/Bioavailability) of Amlodipine
Full Information
NCT ID
NCT02548286
First Posted
August 20, 2015
Last Updated
December 4, 2015
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT02548286
Brief Title
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
Official Title
A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers(B)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
September 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Healthy male volunteer, Candesartan, Amlodipine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Candesartan and Amlodipine
Arm Type
Active Comparator
Arm Description
Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
Arm Title
CKD-330
Arm Type
Experimental
Arm Description
CKD-330 8/5mg, PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
Candesartan 8mg
Intervention Description
PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
Amlodipine 5mg
Intervention Description
PO, 1day or 22day
Intervention Type
Drug
Intervention Name(s)
CKD-330 8/5mg
Intervention Description
PO, 1day or 22day
Primary Outcome Measure Information:
Title
Cmax(Maximum Plasma Concentration) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
AUCt(Area Under the Plasma Concentration-time curve) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
Cmax(Maximum Plasma Concentration) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
AUCt(Area Under the Plasma Concentration-time curve) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Secondary Outcome Measure Information:
Title
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
tmax(Time to reach the maximum concentration) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
t1/2β(Time for C max to drop in half) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
CL/F(Clearance/Bioavailability) of Candesartan
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
Title
AUCinf(Area Under the Plasma Concentration-time curve from time t to infinity) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
tmax(Time to reach the maximum concentration) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
t1/2β(Time for C max to drop in half) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
Title
CL/F(Clearance/Bioavailability) of Amlodipine
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male volunteer in the age of 19-45
Body weight ≥ 55 kg and in the range of calculated IBW ±20%
Subject without a hereditary problems, chronic disease and morbid symptom
Suitable clinical laboratory test values
Subject who sign on an informed consent form willingly
Exclusion Criteria:
Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
Gastrointestinal disease or gastrointestinal surgery
History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
Galactose intolerance
Sitting systolic blood pressure ≥ 140 mmHg or< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or < 60 mmHg, pulse ≥ 100 beats per minute
Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin > 2 x upper limit of normal range
Serum Creatinine > upper limit of normal range
Drug abuse
Subject treated metabolizing enzyme inducers or inhibitors within 1 month
Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
Subject treated Investigational product(include Bioequivalence test) within 3 months
Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
Continuously taking Alcohol > 21 units/week
Cigarette > 10 cigarettes/day
Subjects with planning of dental treatment or any surgery
Another clinical condition in judgement of investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jang Hee Hong, MD, PhD
Organizational Affiliation
Chungnam National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chungnam National University Hospital
City
Daejeon
State/Province
Jung-gu
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
We'll reach out to this number within 24 hrs